New horizons in migraine treatment

Seize the opportunity to offer your patients an innovative and effective treatment method for managing migraine symptoms together with CEFALY^®.

Finding the right treatment is a major challenge for many migraine sufferers

As not all migraine sufferers respond to traditional treatments, finding the right treatment can be extremely difficult. Doctors are faced with the complex task of finding individual solutions for their patients to efficiently relieve migraine symptoms. CEFALY^® offers a promising option, as it is based on neurostimulation technology and aims to treat and prevent migraine. By stimulating the trigeminal nerve, CEFALY^® could potentially be an effective alternative way to improve the quality of life of migraine sufferers.

The first therapeutic choice for the acute and preventive treatment of migraine
(CE marked & FDA aproved)

Acute migraine treatment (ACME study)

Percentage of patients who no longer feel pain after 1 hour

>50% pain reduction after 1 hour

Neuromodulation 2017: Chou, D. E., Gross, G. J., Casadei, C. H., & Yugrakh, M. S. (2017). External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy. Neuromodulation: Technology at the Neural Interface.

Cephalalgia 2019: Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial.

Preventive Migraine Treatment (PREMICE Study)

Migraine reduction

Response rate

Neurology 2013: Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P., & Magis, D. (2013). Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology, 80(8), 697-704.

Journal of Headache and Pain 2015: Russo, A., Tessitore, A., Conte, F., Marcuccio, L., Giordano, A., & Tedeschi, G. (2015). Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience. The Journal of Headache and Pain, 16(1):69.

Safety: Prospective study with 2313 patients

Side effects occur in only 4.3% of all patients compared to an average of 50% for typical oral migraine oral use of migraine medications as part of a preventive as part of a preventive treatment.

Cephalalgia, 2016: Magis, D., D’Ostilio, K., Thibaut, A., De Pasqua, V., Gerard, P., Hustinx, R., ... & Schoenen, J. (2016). Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia, 0333102416656118.